Altimmune, Inc. (ALT) Director Purchases $46,557.90 in Stock
Altimmune, Inc. (NYSEARCA:ALT) Director Derace L. Schaffer bought 26,010 shares of the firm’s stock in a transaction that occurred on Tuesday, December 5th. The shares were purchased at an average cost of $1.79 per share, for a total transaction of $46,557.90. Following the completion of the transaction, the director now owns 300,373 shares of the company’s stock, valued at $537,667.67. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Altimmune, Inc. has a 1-year low of $49.37 and a 1-year high of $54.24.
Separately, Piper Jaffray Companies assumed coverage on Altimmune in a report on Monday, October 9th. They set an “overweight” rating and a $6.00 price objective on the stock.
ILLEGAL ACTIVITY WARNING: “Altimmune, Inc. (ALT) Director Purchases $46,557.90 in Stock” was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another website, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.americanbankingnews.com/2017/12/05/altimmune-inc-alt-director-purchases-46557-90-in-stock.html.
iShares Diversified Alternatives Trust (the Trust) is a commodity pool. The investment objective of the Trust is to maximize absolute returns from its investments in certain futures and/or forward contracts. The Trust holds long and/or short positions in foreign currency forward contracts and exchange-traded futures contracts involving assets, such as commodities, currencies, interest rates or certain eligible stock and/or bond indices.
Receive News & Ratings for Altimmune Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altimmune Inc. and related companies with MarketBeat.com's FREE daily email newsletter.